Study S000455

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT02455076
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 150
Start: 2015-09
Primary completion: 2018-03
Lead sponsor: Emory University
Conditions: Type 2 Diabetes
Interventions: DRUG:Exenatide; DRUG:Glargine; DRUG:Rapid-acting insulin analogs
Results posted: TRUE

Registered primary outcomes

Mean Daily Blood Glucose Concentration Inpatient [Duration of hospital stay, an expected average of 10 days.]
Change in HbA1c Concentration Inpatient [12 weeks from discharge.]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023902	A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes. Fayfman M, Diabetes care	2019	Randomized trial	PMID 30679302 DOI	cites ClinicalTrials.gov:NCT02455076; registry reference DERIVED:30679302